Document is current
Any future updates will be listed below
-
Authors
van der Zalm, Amber P. https://orcid.org/0000-0002-3726-1111
Dings, Mark P. G. https://orcid.org/0000-0001-8509-0006
Manoukian, Paul https://orcid.org/0009-0005-1130-8582
Boersma, Hannah
Janssen, Reimer
Bailey, Peter https://orcid.org/0000-0002-0857-2041
Koster, Jan https://orcid.org/0000-0002-0890-7585
Zwijnenburg, Danny
Volckmann, Richard
Bootsma, Sanne
Waasdorp, Cynthia
van Mourik, Monique
Blangé, Dionne
van den Ende, Tom
Oyarce, César I.
Derks, Sarah https://orcid.org/0000-0002-4547-7457
Creemers, Aafke
Ebbing, Eva A.
Hooijer, Gerrit K. https://orcid.org/0000-0002-8993-7101
Meijer, Sybren L.
van Berge Henegouwen, Mark I. https://orcid.org/0000-0001-8689-3134
Medema, Jan Paul
van Laarhoven, Hanneke W. M.
Bijlsma, Maarten F.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (10992)
- License Information
-
More Information
Article History
Received: 1 May 2023
Accepted: 25 April 2024
First Online: 17 May 2024
Competing interests
: M.F.B. has received research funding from Celgene, Frame Therapeutics, and Lead Pharma, and has acted as a consultant to Servier and Olympus. H.W.M.L. Consultant or advisory role: BMS, Daiichy, Dragonfly, Eli Lilly, MSD, Nordic Pharma, Servier. Research funding and/or medication supply: Bayer, BMS, Celgene, Janssen, Incyte, Eli Lilly, MSD, Nordic Pharma, Philips, Roche, Servier. Speaker role: Astellas, Daiichy, Novartis. J.P.M. has acted as a consultant to AbbVie. M.I.v.B.H. served as consultant for Johnson and Johnson, Medtronic, Alesi Surgical, Mylan and has received unrestricted research funding from Stryker. None of these parties were involved in the design of this study or drafting of the manuscript. All other authors have no competing interests to declare.
